-
1.发明申请公开(公告)号：US20220089585A1
公开(公告)日：2022-03-24
申请号：US17422642
申请日：2020-01-10
申请人： Dane James CLAUSEN , Joseph A. KOZLOWSKI , Jian LIU , Scott E. WOLKENBERG , Wensheng YU , Merck Sharp & Dohme Corp.
IPC分类号： C07D413/14 , C07D413/12 , A61K45/06 , A61K31/422 , A61K31/4709 , C07D417/14 , A61P31/18
摘要： The present invention relates to Compounds of Formula I and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, R4, X and A are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treating or preventing HIV infection in a subject.
-
公开(公告)号：US20230365533A1
公开(公告)日：2023-11-16
申请号：US18040896
申请日：2021-08-16
申请人： Stephane L. BOGEN , Dane James CLAUSEN , Deodial Guy GUIADEEN , Jinsong HAO , Shishi LIN , Michael T. RUDD , Lan WEI , Li XIAO , Dexi YANG , MERCK SHARP & DOHME CORP.
发明人： Stephane L. Bogen , Dane James Clausen , Deodial Guy Guiadeen , Jinsong Hao , Shishi Lin , Michael T. Rudd , Lan Wei , Li Xiao , Dexi Yang
IPC分类号： C07D403/12 , C07D403/14 , C07D417/12 , C07D491/048
CPC分类号： C07D403/12 , C07D403/14 , C07D417/12 , C07D491/048
摘要： The present invention is directed to bicyclo[4.1 0]heptane pyrrolidine compounds of formula (I) which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
where
is
wherein n is 0 or 1;-
公开(公告)号：US11098029B2
公开(公告)日：2021-08-24
申请号：US16787201
申请日：2020-02-11
IPC分类号： C07D401/14 , C07D207/16 , C07D403/12 , C07D409/12
摘要： The present invention is directed to 5-alkyl pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
-
4.发明申请公开(公告)号：US20220144837A1
公开(公告)日：2022-05-12
申请号：US17438479
申请日：2020-03-16
发明人： Wensheng Yu , Joseph A. Kozlowski , Dane James Clausen , Jian Liu , James Fells
IPC分类号： C07D471/22 , A61P31/18 , A61K31/4748 , C07D491/18 , C07D498/22 , C07D487/08 , A61K31/438 , A61K31/426 , A61K31/635 , A61K31/4418 , A61K31/506 , A61K31/685 , A61K31/505 , A61K31/4439 , A61K31/52 , A61K31/513
摘要： The present invention relates to Compounds of Formula I and Ia and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, X, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I or Ia, and methods of using the compounds of Formula I or Ia for treating or preventing HIV infection in a subject.
-
5.发明申请公开(公告)号：US20210403479A1
公开(公告)日：2021-12-30
申请号：US17288626
申请日：2019-11-04
发明人： Wensheng Yu , Joseph Kozlowski , Dane James Clausen , Jian Liu , Younong Yu , Ming Wang , Bing Li
IPC分类号： C07D487/10 , C07D403/12 , C07D413/14 , C07D401/14 , C07D401/12 , C07D471/04 , C07D417/14 , C07D498/10 , C07D405/14 , A61K45/06
摘要： The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, R4 and A are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treating or preventing HIV infection in a subject.
-
6.发明申请公开(公告)号：US20210276992A1
公开(公告)日：2021-09-09
申请号：US17261982
申请日：2019-07-26
发明人： Jian Liu , Dane James Clausen , Wensheng Yu , Joseph M. Kelly , Hyunjin M. Kim , Joseph A. Kozlowski
IPC分类号： C07D413/14 , C07D417/14 , C07D471/04 , C07D413/12 , C07D498/10 , C07D487/04 , C07D498/04 , C07D513/04
摘要： The present invention relates to Compounds of Formula (I): Formula (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, Ra, Rb, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treating or preventing HIV infection in a subject.
-
![Azabicyclo[4.1.0]heptane allosteric modulators of the M4 muscarinic acetylcholine receptor](/abs-image/US/2021/03/16/US10945771B2/abs.jpg.150x150.jpg)
7.发明授权公开(公告)号：US10945771B2
公开(公告)日：2021-03-16
申请号：US16620046
申请日：2018-06-04
IPC分类号： A61B17/70 , A61B17/17 , A61B17/34 , A61B17/86 , C07D471/04 , C07D471/14 , C07D498/14 , A61B17/56 , A61B90/00
摘要： The present invention is directed to azabicyclo[4.1.0]heptane compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
-
公开(公告)号：US20230018413A1
公开(公告)日：2023-01-19
申请号：US17632065
申请日：2020-08-03
发明人： Stephane L. Bogen , Ping Chen , Dane James Clausen , Jinsong Hao , Dipannita Kalyani , Michael T. Rudd , Shawn P. Walsh , Lan Wei , Dexi Yang
IPC分类号： C07D403/04 , C07D207/14 , C07D401/04 , C07D471/04 , C07D417/04 , C07D413/10 , C07D417/14 , C07D413/04 , C07D409/04 , C07D405/04 , C07D498/04 , C07D491/048
摘要： The present invention is directed to heteroaryl pyrrolidine and piperidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
-
公开(公告)号：US20220144771A1
公开(公告)日：2022-05-12
申请号：US17430409
申请日：2020-02-11
发明人： Stephane L. Bogen , Michael J. Breslin , Dane James Clausen , Anthony Ginnetti , Michael T. Rudd , Shawn J. Stachel , Craig A. Stump , Dexi Yang
IPC分类号： C07D207/14
摘要： The present invention is directed to pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.031 秒)
